Autocrine, paracrine and juxtacrine signaling by EGFR ligands.

Receptor and cytoplasmic protein tyrosine kinases play prominent roles in the control of a range of cellular processes during embryonic development and in the regulation of many metabolic and physiological processes in a variety of tissues and organs. The epidermal growth factor receptor (EGFR) is a well-known and versatile signal transducer that has been highly conserved during evolution. It functions in a wide range of cellular processes, including cell fate determination, proliferation, cell migration and apoptosis. The number of ligands that can activate the EGF receptor has increased during evolution. These ligands are synthesized as membrane-anchored precursor forms that are later shed by metalloproteinase-dependent cleavage to generate soluble ligands. In certain circumstances the membrane anchored isoforms as well as soluble growth factors may also act as biologically active ligands; therefore depending on the circumstances these ligands may induce juxtacrine, autocrine, paracrine and/or endocrine signaling. In this review, we discuss the different ways that EGFR ligands can activate the receptor and the possible biological implications.

[1]  R. Derynck,et al.  Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor , 1995, Nature.

[2]  B. Shilo,et al.  A thousand and one roles for the Drosophila EGF receptor. , 1997, Trends in genetics : TIG.

[3]  B. Lindeman,et al.  Endocytosed epidermal growth factor (EGF) receptors contribute to the EGF-mediated growth arrest in A431 cells by inducing a sustained increase in p21/CIP1. , 1998, Experimental cell research.

[4]  A. Ullrich,et al.  EGFR signal transactivation in cancer cells. , 2003, Biochemical Society transactions.

[5]  J. Lysiak,et al.  Localization of amphiregulin in the human placenta and decidua throughout gestation: role in trophoblast growth. , 1995, Placenta.

[6]  Paul W. Sternberg,et al.  The let-23 gene necessary for Caenorhabditis elegans vulval induction encodes a tyrosine kinase of the EGF receptor subfamily , 1990, Nature.

[7]  G. Gill,et al.  The EGF receptor: structure, regulation and potential role in malignancy. , 1985, Cancer surveys.

[8]  Xin-Fu Zhou,et al.  Roles of transforming growth factor-α and related molecules in the nervous system , 1999, Molecular Neurobiology.

[9]  M. Sliwkowski,et al.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.

[10]  T. Magnuson,et al.  Targeted disruption of the epidermal growth factor receptor impairs growth of squamous papillomas expressing the v-ras(Ha) oncogene but does not block in vitro keratinocyte responses to oncogenic ras. , 1997, Cancer research.

[11]  R. Ezzell,et al.  Mouse preimplantation blastocysts adhere to cells expressing the transmembrane form of heparin-binding EGF-like growth factor. , 1996, Development.

[12]  H. Gralnick,et al.  Novel function for beta 1 integrins in keratinocyte cell-cell interactions , 1990, The Journal of cell biology.

[13]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[14]  David C. Lee,et al.  Defective valvulogenesis in HB‐EGF and TACE‐null mice is associated with aberrant BMP signaling , 2003, The EMBO journal.

[15]  Robert J Coffey,et al.  EGF receptor ligands. , 2003, Experimental cell research.

[16]  M. Klagsbrun,et al.  Matrix Metalloproteinase-3 Releases Active Heparin-binding EGF-like Growth Factor by Cleavage at a Specific Juxtamembrane Site* , 1997, The Journal of Biological Chemistry.

[17]  Hiroshi Asanuma,et al.  Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy , 2002, Nature Medicine.

[18]  Kuo-Fen Lee,et al.  Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.

[19]  M. Bush,et al.  Evidence of Juxtacrine Signaling for Transforming Growth Factor α inHuman Endometrium , 1998 .

[20]  Monilola A. Olayioye,et al.  The ErbB receptor tyrosine family as signal integrators. , 2001, Endocrine-related cancer.

[21]  P. Sternberg,et al.  C. elegans Vulval Development as a Model System to Study the Cancer Biology of EGFR Signaling , 2004, Cancer and Metastasis Reviews.

[22]  P. Dempsey,et al.  Emerging roles of TACE as a key protease in ErbB ligand shedding. , 2002, Molecular interventions.

[23]  R. Kurten.  Sorting motifs in receptor trafficking. , 2003, Advanced drug delivery reviews.

[24]  Jin Chen,et al.  The ephrins and Eph receptors in angiogenesis. , 2002, Cytokine & growth factor reviews.

[25]  Alan Wells,et al.  Effect of Epidermal Growth Factor Receptor Internalization on Regulation of the Phospholipase C-γ1 Signaling Pathway* , 1999, The Journal of Biological Chemistry.

[26]  E. Mekada,et al.  Membrane-anchored heparin-binding EGF-like growth factor (HB-EGF) and diphtheria toxin receptor-associated protein (DRAP27)/CD9 form a complex with integrin alpha 3 beta 1 at cell-cell contact sites , 1995, The Journal of cell biology.

[27]  B. Mroczkowski,et al.  Identification of biologically active epidermal growth factor precursor in human fluids and secretions. , 1993, Endocrinology.

[28]  M. Koyama,et al.  Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA , 1993, The Journal of experimental medicine.

[29]  David C. Lee,et al.  Tumor Necrosis Factor-α Converting Enzyme (TACE) Regulates Epidermal Growth Factor Receptor Ligand Availability* , 2002, The Journal of Biological Chemistry.

[30]  E. Mekada,et al.  Contact-dependent Growth Inhibition and Apoptosis of Epidermal Growth Factor (EGF) Receptor-expressing Cells by the Membrane-anchored Form of Heparin-binding EGF-like Growth Factor* , 1999, The Journal of Biological Chemistry.

[31]  R. Coffey,et al.  Basolateral targeting and efficient consumption of transforming growth factor-alpha when expressed in Madin-Darby canine kidney cells. , 1994, The Journal of biological chemistry.

[32]  A. Wells,et al.  Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement , 1994, The Journal of cell biology.

[33]  Stanley Cohen,et al.  Epidermal growth factor , 1987, In Vitro Cellular & Developmental Biology.

[34]  M. Rudnicki,et al.  ErbB2 Is Required for Muscle Spindle and Myoblast Cell Survival , 2002, Molecular and Cellular Biology.

[35]  E. Mekada,et al.  Heparin-binding EGF-like growth factor: a juxtacrine growth factor. , 2000, Cytokine & growth factor reviews.

[36]  Philippe Soriano,et al.  Ephrin signaling in vivo: Look both ways , 2005, Developmental dynamics : an official publication of the American Association of Anatomists.

[37]  K. Sengoku,et al.  The soluble and membrane-anchored forms of heparin-binding epidermal growth factor-like growth factor appear to play opposing roles in the survival and apoptosis of human luteinized granulosa cells. , 2002, Molecular human reproduction.

[38]  S. Inui,et al.  Possible role of coexpression of CD9 with membrane‐anchored heparin‐binding EGF‐like growth factor and amphiregulin in cultured human keratinocyte growth , 1997, Journal of cellular physiology.

[39]  Cori Bargmann,et al.  The neu oncogene encodes an epidermal growth factor receptor-related protein , 1986, Nature.

[40]  G. Besner,et al.  Heparin-binding EGF-like growth factor is present in human amniotic fluid and breast milk. , 2002, Journal of pediatric surgery.

[41]  R. Fridman,et al.  Epidermal growth factor and amphiregulin up‐regulate matrix metalloproteinase‐9 (MMP‐9) in human breast cancer cells , 1997, International journal of cancer.

[42]  C. Arteaga,et al.  The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. , 2003, Seminars in oncology.

[43]  Alan Wells,et al.  STAT Activation by Epidermal Growth Factor (EGF) and Amphiregulin , 1996, The Journal of Biological Chemistry.

[44]  K. Brown.  The epidermal growth factor/transforming growth factor-alpha family and their receptors. , 1995, European Journal of Gastroenterology and Hepathology.

[45]  B. Sordat,et al.  Differential display cloning identifies motility-related protein (MRP1/CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells. , 1997, Cancer research.

[46]  S. Itoi,et al.  Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. , 1996, Cancer research.

[47]  R. Auger,et al.  Regulated Cell Surface Pro-EGF Ectodomain Shedding Is a Zinc Metalloprotease-dependent Process* , 2003, Journal of Biological Chemistry.

[48]  J. Massagué,et al.  Juxtacrine cell signaling molecules. , 1993, Current opinion in cell biology.

[49]  D A Lauffenburger,et al.  Intracellular Trafficking of Epidermal Growth Factor Family Ligands Is Directly Influenced by the pH Sensitivity of the Receptor/Ligand Interaction (*) , 1995, The Journal of Biological Chemistry.

[50]  Y. Yarden,et al.  The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions , 1997, FEBS letters.

[51]  M. Klagsbrun,et al.  Extracellular calcium influx stimulates metalloproteinase cleavage and secretion of heparin‐binding EGF‐like growth factor independently of protein kinase C , 1998, Journal of cellular biochemistry.

[52]  D. Stern,et al.  Specificity within the EGF family/ErbB receptor family signaling network , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[53]  M. S. Murphy,et al.  Growth factors and the gastrointestinal tract. , 1998, Nutrition.

[54]  H. Wiley,et al.  Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. , 2001, Molecular biology of the cell.

[55]  T. Mitamura,et al.  Heparin‐binding EGF‐like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up‐regulates functional receptors and diphtheria toxin sensitivity. , 1994, The EMBO journal.

[56]  J. Grandis,et al.  Epidermal Growth Factor Receptor-stimulated Activation of Phospholipase Cγ-1 Promotes Invasion of Head and Neck Squamous Cell Carcinoma , 2003 .

[57]  D. Warburton,et al.  Abrogation of tumor necrosis factor-alpha converting enzyme inhibits embryonic lung morphogenesis in culture. , 2001, The International journal of developmental biology.

[58]  Z. Werb,et al.  G protein–coupled receptors , 2002 .

[59]  R. Harris,et al.  Membrane-associated HB-EGF modulates HGF-induced cellular responses in MDCK cells , 2004, Journal of Cell Science.

[60]  S. Levy,et al.  The tetraspanin superfamily: molecular facilitators , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[61]  M. Iorio,et al.  Role of HER receptors family in development and differentiation , 2004, Journal of cellular physiology.

[62]  Joseph Schlessinger,et al.  Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor , 2002, Cell.

[63]  H. Steven Wiley,et al.  Regulation of Receptor Tyrosine Kinase Signaling by Endocytic Trafficking , 2001, Traffic.

[64]  H. Aberle,et al.  Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor , 1994, The Journal of cell biology.

[65]  T. Patel,et al.  The Juxtamembrane, Cytosolic Region of the Epidermal Growth Factor Receptor Is Involved in Association with α-Subunit of Gs* , 1997, The Journal of Biological Chemistry.

[66]  W. Kao,et al.  Corneal Epithelial Wound Healing , 2001, Experimental biology and medicine.

[67]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[68]  J. Watson,et al.  Cloning and Biological Activity of Epigen, a Novel Member of the Epidermal Growth Factor Superfamily* , 2001, The Journal of Biological Chemistry.

[69]  D. Lauffenburger,et al.  Internalized Epidermal Growth Factor Receptors Participate in the Activation of p21 ras in Fibroblasts* , 1999, The Journal of Biological Chemistry.

[70]  David C. Lee,et al.  TACE/ADAM17 Processing of EGFR Ligands Indicates a Role as a Physiological Convertase , 2003, Annals of the New York Academy of Sciences.

[71]  R. Harris.  Potential physiologic roles for epidermal growth factor in the kidney. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[72]  R. Harris,et al.  Role of membrane-bound heparin-binding epidermal growth factor-like growth factor (HB-EGF) in renal epithelial cell branching. , 2002, Kidney international.

[73]  N. Shimizu,et al.  Detection of Epidermal Growth Factor Receptors and E‐Cadherins in the Basolateral Membrane of A431 Cells by Laser Scanning Fluorescence Microscopy , 1991, Japanese journal of cancer research : Gann.

[74]  M. Klagsbrun,et al.  Activation of HER4 by heparin‐binding EGF‐like growth factor stimulates chemotaxis but not proliferation , 1997, The EMBO journal.

[75]  T. Mitamura,et al.  Importance of the Major Extracellular Domain of CD9 and the Epidermal Growth Factor (EGF)-like Domain of Heparin-binding EGF-like Growth Factor for Up-regulation of Binding and Activity* , 2000, The Journal of Biological Chemistry.

[76]  P. Seeburg,et al.  Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells , 1984, Nature.

[77]  G. M. Walton,et al.  Ligand-induced endocytosis of the EGF receptor is blocked by mutational inactivation and by microinjection of anti-phosphotyrosine antibodies , 1988, Cell.

[78]  K. Maeda,et al.  pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[79]  Roy S Herbst,et al.  Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. , 2002, Seminars in oncology.

[80]  M. Freeman,et al.  Regulated Intracellular Ligand Transport and Proteolysis Control EGF Signal Activation in Drosophila , 2001, Cell.

[81]  E. Mekada,et al.  A metalloprotease–disintegrin, MDC9/meltrin‐γ/ADAM9 and PKCδ are involved in TPA‐induced ectodomain shedding of membrane‐anchored heparin‐binding EGF‐like growth factor , 1998, The EMBO journal.

[82]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[83]  D. Riethmacher,et al.  Severe neuropathies in mice with targeted mutations in the ErbB3 receptor , 1997, Nature.

[84]  Edouard C. Nice,et al.  Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.

[85]  G. Weskamp,et al.  Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands , 2004, The Journal of cell biology.

[86]  Jian-Kang Chen,et al.  Importance of functional EGF receptors in recovery from acute nephrotoxic injury. , 2003, Journal of the American Society of Nephrology : JASN.

[87]  D. Salomon,et al.  Processing and juxtacrine activity of membrane‐anchored betacellulin , 1999, Journal of cellular biochemistry.

[88]  R. Harris,et al.  Coexpression of CD9 augments the ability of membrane-bound heparin-binding epidermal growth factor-like growth factor (proHB-EGF) to preserve renal epithelial cell viability. , 1999, Kidney international.

[89]  D. Fisher,et al.  Immunocytochemical localization of epidermal growth factor in mouse kidney. , 1986, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[90]  M. Klagsbrun,et al.  The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor , 1995, The Journal of cell biology.

[91]  R. Derynck,et al.  The Tetraspanin Cd9 Associates with Transmembrane TGF-α and Regulates TGF-α–Induced Egf Receptor Activation and Cell Proliferation , 2000, The Journal of cell biology.

[92]  M. Rosenfeld,et al.  Alteration of epidermal growth factor receptor activity by mutation of its primary carboxyl-terminal site of tyrosine self-phosphorylation. , 1988, The Journal of biological chemistry.

[93]  L. Graves,et al.  Angiotensin II stimulates ERK via two pathways in epithelial cells: protein kinase C suppresses a G–protein coupled receptor–EGF receptor transactivation pathway , 1998, The EMBO journal.

[94]  J. Massagué,et al.  Cell-cell adhesion mediated by binding of membrane-anchored transforming growth factor alpha to epidermal growth factor receptors promotes cell proliferation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[95]  J. Baselga,et al.  TACE is required for the activation of the EGFR by TGF‐α in tumors , 2003 .

[96]  A. Ullrich,et al.  Signal characteristics of G protein‐transactivated EGF receptor , 1997, The EMBO journal.

[97]  D. Lowy,et al.  The biological activity of the human epidermal growth factor receptor is positively regulated by its C-terminal tyrosines. , 1991, Oncogene.

[98]  A. Ullrich,et al.  Epidermal growth factor receptors: critical mediators of multiple receptor pathways. , 1999, Current opinion in cell biology.

[99]  D. Lauffenburger,et al.  Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[100]  D. Lauffenburger,et al.  EGF receptor regulation of cell motility: EGF induces disassembly of focal adhesions independently of the motility-associated PLCgamma signaling pathway. , 1998, Journal of cell science.

[101]  S. Belmadani,et al.  Involvement of Metalloproteinases 2/9 in Epidermal Growth Factor Receptor Transactivation in Pressure-Induced Myogenic Tone in Mouse Mesenteric Resistance Arteries , 2004, Circulation.

[102]  I. Dikic,et al.  Cbl–CIN85–endophilin complex mediates ligand-induced downregulation of EGF receptors , 2002, Nature.

[103]  I Dikic,et al.  Mechanisms controlling EGF receptor endocytosis and degradation. , 2003, Biochemical Society transactions.

[104]  D. Fisher,et al.  Immunoelectron microscopy of epidermal growth factor in mouse kidney. , 1986, Journal of ultrastructure and molecular structure research.

[105]  Rüdiger Klein,et al.  Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor , 1995, Nature.

[106]  P. Boquet,et al.  Functional analysis of four tetraspans, CD9, CD53, CD81, and CD82, suggests a common role in costimulation, cell adhesion, and migration: only CD9 upregulates HB-EGF activity. , 1997, Cellular immunology.

[107]  E. Wagner,et al.  Strain-dependent epithelial defects in mice lacking the EGF receptor. , 1995, Science.

[108]  M. Klagsbrun,et al.  Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. , 1995, Molecular biology of the cell.

[109]  A. Ullrich,et al.  Functional analysis of the ligand binding site of EGF‐receptor utilizing chimeric chicken/human receptor molecules. , 1989, The EMBO journal.

[110]  D. Warburton,et al.  TACE is required for fetal murine cardiac development and modeling. , 2003, Developmental biology.

[111]  S. Cohen,et al.  The stimulation of epidermal proliferation by a specific protein (EGF). , 1965, Developmental biology.